Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers

K E Dooley, E E Bliven-Sizemore, M Weiner, Y Lu, E L Nuermberger, W C Hubbard, E J Fuchs, M T Melia, W J Burman, S E Dorman, K E Dooley, E E Bliven-Sizemore, M Weiner, Y Lu, E L Nuermberger, W C Hubbard, E J Fuchs, M T Melia, W J Burman, S E Dorman

Abstract

Rifapentine (RP T) is an antituberculosis drug that may shorten treatment duration when substituted for rifampin (RI F).The maximal tolerated daily dose of RP T and its potential for cytochrome 3A4 induction and autoinduction at clinically relevant doses are unknown. In this phase I, dose-escalation study among healthy volunteers, daily doses as high asa prespecified maximum of 20 mg/kg/day were well tolerated. Steady-state RP T concentrations increased with dose from 5 to 15 mg/kg, but area under the plasma concentration–time curve (AU C0–24) and maximum concentration (Cmax)were similar in the 15- and 20-mg/kg cohorts. Although RP T pharmacokinetics (PK) appeared to be time-dependent,accumulation occurred with daily dosing. The mean AU C0–12 of oral midazolam (MDZ), a cytochrome 3A (CYP 3A) probe drug, was reduced by 93% with the coadministration of RPT and by 74% with the coadministration of RIF (P < 0.01).Changes in the oral clearance of MDZ did not vary by RP T dose. In conclusion, RP T was tolerated at doses as high as20 mg/kg/day, its PK were less than dose-proportional, and its CYP 3A induction was robust.

Conflict of interest statement

CONFLICT OF INTEREST

The authors declared no conflict of interest.

Figures

Figure 1
Figure 1
Participant flow in Tuberculosis Trials Consortium Study 29B. PK, pharmacokinetics.
Figure 2
Figure 2
Single-dose and multiple-dose rifapentine (RPT) and desacetylrifapentine (desRPT) concentrations. (a) Mean plasma RPT concentrations (μg/ml) vs. time after single doses of 5 mg/kg (open triangles), 10 mg/kg (open circles), 15 mg/kg (filled circles), or 20 mg/kg (filled squares). (b) Mean plasma RPT concentrations vs. time after 14 daily doses of 5 mg/kg (open triangles), 10 mg/kg (open circles), 15 mg/kg (filled circles), or 20 mg/kg (filled squares). (c) Mean plasma desRPT concentrations vs. time after single doses of 5 mg/kg (open triangles), 10 mg/kg (open circles), 15 mg/kg (filled circles), or 20 mg/kg (filled squares) of RPT. (d) Mean plasma desRPT concentrations vs. time after 14 daily doses of 5 mg/kg (open triangles), 10 mg/kg (open circles), 15 mg/kg (filled circles), or 20 mg/kg (filled squares) of RPT. The values shown represent arithmetic means with SE bars.
Figure 3
Figure 3
Mean (SD) values of (a) Cmax and (b) AUC0–12 of midazolam (MDZ) and 1-OH-midazolam (OH-MDZ) when oral MDZ (15 mg) is coadministered with steady-state rifampin (RIF) or rifapentine (RPT), expressed as percentages of the respective concentrations when MDZ (15 mg) is administered alone. AUC, area under the concentration–time curve; Cmax, maximum concentration.
Figure 4
Figure 4
Schematic of the dosing regimen and sample collection for pharmacokinetic testing.

Source: PubMed

3
Abonnieren